Asthma, Allergic Clinical Trial
Official title:
A Phase 2 Multi-centre Randomized Double-blind Placebo-controlled Parallel Group Study to Examine the Effects of 24 Weeks Tezepelumab 210 mg sc q4wks on Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma
Asthma is a condition where small inhaled particles can cause inflammation in the lung leading to constriction of airways and wheeze. Mast cells are immune cells in airways that can release chemical causing constriction of the airways and wheeze. Tezepelumab is an injectable medication that improves asthma by stopping inflammation, but the effect on mast cells is not known. Tezepelumab was approved in Canada July 2022 for treatment of severe asthma. Tezepelumab is not approved for treatment of mild asthma by any health authority, except for use in research studies like this. This study will examine the effect of tezepelumab on mast cells and airway constriction to understand the mechanisms of asthma, and which patients will benefit most from drugs like tezepelumab.
Status | Not yet recruiting |
Enrollment | 34 |
Est. completion date | December 30, 2024 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Provision of informed consent prior to any study specific procedures 2. Male and female 18 through 65 years of age 3. Positive skin-prick test to a common aeroallergen 4. Methacholine PD20 = 200mcg 5. Mannitol DRR = 42.3mg/FEV1 %f all (equivalent to PD15 = 635mg) 6. Baseline FEV1 = 70% of the predicted value 7. Negative pregnancy test (urine) for female participants of childbearing potential. Exclusion Criteria: 1. Current or former smoker with >10-pack-year history 2. Current or previous history of lung disease other than mild stable allergic asthma 3. Significant systemic disease, including history of current malignancy or autoimmune disease 4. Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site) 5. Previous randomisation in the present study. Re-screening (Week -1) for FEV1 and AHR is permitted once for each test. 6. Participation in another clinical study with an investigational product during the last 30 days or 5 half-lives of the drug (whichever is longer) 7. Use of any medications for treatment of asthma other than prophylactic short-acting ß2-agonists, or use of short-acting ß2-agonists for relief of symptoms less than once weekly. 8. Participants with known hypersensitivity to tezepelumab or any of the excipients of the product. 9. Positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody, at screening 10. Known to have tested positive for human immunodeficiency virus 11. Known history of drug or alcohol abuse within 1 year of screening 12. For women only - currently pregnant (confirmed with positive pregnancy test) or breast feeding. 13. Unwillingness or inability to comply with the study protocol for any other reason. |
Country | Name | City | State |
---|---|---|---|
Canada | McMaster University | Hamilton | Ontario |
Canada | University of Saskatchewan | Saskatoon | Saskatchewan |
Lead Sponsor | Collaborator |
---|---|
McMaster University | University of Saskatchewan |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Methacholine PD20 | The provocative dose of methacholine causing 20% fall in FEV1 | Week -1 to Week 24 | |
Secondary | Dose response ratio to mannitol | The mannitol dose response ratio calculated by dividing the total cumulative dose by the % fall in FEV1 at that dose. | Week -1 to Week 24 | |
Secondary | Mast cell tryptase levels. | Level of mast cell-derived tryptase in blood and urine at Week 24. | Week -1 to Week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04435990 -
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
|
Phase 3 | |
Completed |
NCT03563521 -
Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
|
||
Completed |
NCT02990117 -
ICS Treatment Compliance of Asthma Patients
|
||
Completed |
NCT03468790 -
Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.
|
Phase 3 | |
Recruiting |
NCT04898283 -
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
|
Phase 3 | |
Recruiting |
NCT03455959 -
Lung-Resident Memory Th2 Cells in Asthma
|
N/A | |
Not yet recruiting |
NCT05352126 -
Effects of Puressentiel Purifying Spray on Asthma Control in Patients With Mild to Moderate Allergy-induced Asthma.
|
N/A | |
Completed |
NCT01104012 -
Validation of Proteomic Analyses for Allergic Asthma and Rhinitis
|
N/A | |
Not yet recruiting |
NCT06027073 -
Biologics and Sublingual Immunotherapy
|
Phase 4 | |
Recruiting |
NCT05720325 -
Dupilumab Effects Against Aeroallergen Challenge
|
Phase 2 | |
Completed |
NCT03112577 -
Study of REGN3500 and Dupilumab in Patients With Asthma
|
Phase 1 | |
Recruiting |
NCT04891237 -
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
|
Phase 3 | |
Terminated |
NCT02953106 -
Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis
|
Phase 4 | |
Completed |
NCT06063044 -
Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
|
||
Completed |
NCT03705325 -
Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer
|
N/A | |
Recruiting |
NCT05478824 -
IL13 Signaling in Allergic Asthma
|
||
Suspended |
NCT04109807 -
Effects of Low Dose Ozone on Airway Inflammatory Responses in Adults With Asthma - Sedentary Nasal Ozone (Asthma SNOZ)
|
N/A | |
Withdrawn |
NCT04035109 -
Anakinra as a Rescue Treatment for Allergic Inflammation
|
Phase 1/Phase 2 | |
Recruiting |
NCT03983603 -
Plant Stanol Esters and Preventing Asthma Symptoms
|
N/A |